Hans‐Jakob Steiger

The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H

Reoperation after Burrhole Surgery - Machine Learning for Risk Stratification of Recurrence rates in Operated Chronic Subdural Hematomas

Stereotactic Radiosurgery for Benign Cavernous Sinus Meningiomas: A Multicentre Study and Review of the Literature

Progenitor cells derived from gene‐engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology

Surgical treatment of brainstem cavernous malformations: an international Delphi consensus

Overexpression of Cystine/Glutamate Antiporter xCT Correlates with Nutrient Flexibility and ZEB1 Expression in Highly Clonogenic Glioblastoma Stem-like Cells (GSCs)

A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma

Different Calculation Strategies Are Congruent in Determining Chemotherapy Resistance of Brain Tumors In Vitro

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development

Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma <i>in vitro</i>

EPEN-34. HIGH-THROUGHPUT DRUG SCREENING OF PRIMARY CULTURES REVEALS IRREVERSIBLE ERBB2 INHIBITION AS NOVEL THERAPEUTIC VULNERABILITY OF EPENDYMOMAS

CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells

Evaluation of a Murine Single-Blood-Injection SAH Model

Local Delivery of Nimodipine by Prolonged-Release Microparticles—Feasibility, Effectiveness and Dose-Finding in Experimental Subarachnoid Hemorrhage